Related Experiment Videos
Chromosomal studies in diabetic patients treated with chlorpropamide
Summary
Chlorpropamide treatment in diabetic patients significantly increased sister chromatid exchanges in chromosomes. However, no significant increase in structural chromosomal aberrations was observed in treated individuals compared to controls.
Area of Science:
- Cytogenetics
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus is a complex metabolic disorder.
- Chlorpropamide is an oral hypoglycemic agent used to manage type 2 diabetes.
- Chromosomal aberrations can indicate genotoxic effects of medications.
Purpose of the Study:
- To investigate the potential genotoxic effects of chlorpropamide on chromosomes in diabetic patients.
- To compare chromosomal changes in patients treated with chlorpropamide against healthy and untreated diabetic controls.
Main Methods:
- Peripheral blood samples were collected from nine diabetic patients treated with chlorpropamide, nine healthy controls, and nine untreated diabetic controls.
- Sister chromatid exchanges (SCEs) and structural chromosomal aberrations were analyzed per metaphase.
- Data from treated patients were compared to pooled control group data.
Main Results:
- A statistically significant increase in sister chromatid exchanges per metaphase was observed in all chlorpropamide-treated patients compared to controls.
- No significant increase in the number of structural chromosomal aberrations was found in treated patients relative to controls.
Conclusions:
- Chlorpropamide treatment may induce a clastogenic or aneugenic effect, as indicated by increased sister chromatid exchanges.
- Chlorpropamide does not appear to significantly increase structural chromosomal aberrations in peripheral blood lymphocytes.